SCYNEXIS faced an extraordinary challenge: launching Brexafemme, a groundbreaking prescription oral treatment designed to eliminate the yeast causing infections, in September 2021. As the first modern oral antifungal treatment to enter the market, Brexafemme represented a revolutionary advancement in its field. However, the stakes were high, and the pressure to execute a flawless commercial launch was immense.
Despite the innovation behind the product, SCYNEXIS was significantly underprepared from an operational perspective. They had no defined IT strategy, limited systems in place, and no dedicated IT infrastructure to support the complexities of a commercial launch. The lack of foundational technology and strategic alignment posed a serious risk to the success of bringing such a transformative treatment to market.
The path to launch required nothing short of building the technological and operational capabilities from the ground up, ensuring that Brexafemme could make its mark as a modern solution for patients in need.
The Tailwinds Advisory Solution: Paving the Way for SCYNEXIS’s Historic Launch
When SCYNEXIS faced the daunting task of launching Brexafemme without the necessary IT infrastructure or strategic support, Tailwinds Advisory stepped in with a transformative approach, ensuring the success of the first modern oral antifungal treatment on the market.
Developed a Multi-Year IT Strategy and RoadmapTailwinds crafted a visionary, multi-year IT strategy that aligned with SCYNEXIS’s immediate goals for Brexafemme while establishing a scalable framework for future growth. The roadmap served as a guiding compass, detailing milestones and ensuring alignment with commercial objectives.
Led Support Program ManagementTailwinds took charge of program management, coordinating cross-functional teams and ensuring smooth execution of all IT-related activities. With expert oversight, the team mitigated risks, resolved challenges in real time, and kept the project on track to meet the September 2021 launch deadline.
Conducted Solution and Vendor Evaluation and SelectionTailwinds identified and evaluated best-fit solutions and vendors, selecting partners that could meet the unique demands of launching a first-in-class treatment. The rigorous evaluation process ensured that SCYNEXIS was equipped with reliable, cutting-edge tools and technologies.
Designed an Enterprise IT ArchitectureStarting from scratch, Tailwinds built a robust enterprise IT architecture capable of supporting the operational complexities of a commercial launch. This architecture included integrations for patient access, prescribing workflows, and sales support, ensuring seamless functionality.
Implemented IT Governance and SecurityRecognizing the critical importance of compliance and data security in the pharmaceutical industry, Tailwinds introduced a comprehensive IT governance framework. By prioritizing data protection and regulatory compliance, they established trust and reliability within the ecosystem.
Planned and Managed IT BudgetTailwinds developed a meticulously detailed IT budget, balancing cost efficiency with the need for advanced solutions. This financial planning allowed SCYNEXIS to allocate resources effectively, ensuring the IT foundation was both sustainable and impactful.
Established an IT OrganizationTo ensure the sustainability of the IT infrastructure, Tailwinds built a dedicated IT organization for SCYNEXIS. This included defining roles, hiring key personnel, and creating operational workflows that empowered the team to manage and scale IT operations independently post-launch.
The Result
Through these targeted and expertly executed initiatives, Tailwinds Advisory transformed a monumental challenge into a groundbreaking success story. SCYNEXIS was equipped with the technology, strategy, and organizational framework needed to confidently launch Brexafemme on time and set the stage for long-term commercial success. Tailwinds’ innovative approach ensured that SCYNEXIS not only met the immediate needs of the Brexafemme launch but also emerged as a stronger, more capable organization ready to tackle future challenges.